Cognition
Study
Ten tested cognitive-enhancement products included unapproved drugs and unpredictable combinations. Such products cannot be assumed to deliver the identity or amount stated on their labels.1
Mind & sleepSmall molecule
Omberacetam (Noopept)
Dipeptide-derived nootropic
No FDA-approved product identified for this exact research entry in the targeted review.
What does it do?
Molecular information
3Amino-acid sequence
An exact sequence has not been verified for this formulation.
LengthNot independently verified
Molecular weight · DaNot independently verified
Molecular formulaNot independently verified3
The exact formulation, clinical benefits and long-term safety require further verification.
Pharmacokinetics
Reported half-lifeHuman half-life not verified3
No numerical human elimination estimate was verified for the exact material in this review.
No numerical estimate was found in the checked data or Pep-Pedia profile. A curve would require an unsupported assumption.
What to expect
Study outcomes
Product quality is a documented concern
Contemporary confirmatory clinical benefit was not verified in this targeted check.1
Reported timelines
Reference & communityOral: days 1–3 through weeks 4–8; after stopping 1–2 weeks
Community/reference cognition reports, not validated milestones.8
Nasal: 5–15 min onset, about 1h peak, 2–4h taper
Source-reported, not confirmed human PK.8
These are reported timelines, not a prediction of your response.
Doses & schedules
Route
Scroll to compare all columns →
| Route | Dose | Frequency | Goal / evidence | Duration | References |
|---|---|---|---|---|---|
| OralOral (Sublingual or swallowed) | 10 mg | 1-2 times daily | Cognitive enhancement (beginner)Reference report | 4-8 weeks continuous use recommended | 8 |
Population Population not independently verified; see the reference and linked research. Context Reported in Pep-Pedia’s educational protocol table. Study attribution and applicability to this exact product are not independently established. Source interaction and mandatory-choline claims are not established clinical rules. Source tabs Oral | |||||
| OralOral, taken with or without food | 10-20 mg | 2-3 times daily | Standard cognitive supportReference report | 4-8 weeks continuous use recommended | 8 |
Population Population not independently verified; see the reference and linked research. Context Reported in Pep-Pedia’s educational protocol table. Study attribution and applicability to this exact product are not independently established. Source interaction and mandatory-choline claims are not established clinical rules. Source tabs Oral | |||||
| OralOral, cycled 4-8 weeks | 20-30 mg | 2-3 times daily | Intensive cognitive enhancementReference report | 4-8 weeks continuous use recommended | 8 |
Population Population not independently verified; see the reference and linked research. Context Reported in Pep-Pedia’s educational protocol table. Study attribution and applicability to this exact product are not independently established. Source interaction and mandatory-choline claims are not established clinical rules. Source tabs Oral | |||||
| OralOral (as studied in clinical trials) | 20 mg | Twice daily | Cognitive recovery supportReference report | 4-8 weeks continuous use recommended | 8 |
Population Population not independently verified; see the reference and linked research. Context Reported in Pep-Pedia’s educational protocol table. Study attribution and applicability to this exact product are not independently established. Source interaction and mandatory-choline claims are not established clinical rules. Source tabs Oral | |||||
| OtherSublingual for enhanced absorption | 5-10 mg | Once daily | Conservative/sensitive individualsReference report | 4-8 weeks continuous use recommended | 8 |
Population Population not independently verified; see the reference and linked research. Context Reported in Pep-Pedia’s educational protocol table. Study attribution and applicability to this exact product are not independently established. Source interaction and mandatory-choline claims are not established clinical rules. Source tabs Oral | |||||
| IntranasalNasal solution | 5-10 mg | 1-2 times daily | Rapid cognitive supportReference report | 2-4 weeks maximum continuous use | 8 |
Population Population not independently verified; see the reference and linked research. Context Reported in Pep-Pedia’s educational protocol table. Study attribution and applicability to this exact product are not independently established. Source interaction and mandatory-choline claims are not established clinical rules. Source tabs Nasal | |||||
| IntranasalNasal spray | 10-15 mg | Once daily | Research applicationsReference report | 2-4 weeks maximum continuous use | 8 |
Population Population not independently verified; see the reference and linked research. Context Reported in Pep-Pedia’s educational protocol table. Study attribution and applicability to this exact product are not independently established. Source interaction and mandatory-choline claims are not established clinical rules. Source tabs Nasal | |||||
| IntranasalNasal | 3-5 mg | Once daily | Conservative approachReference report | 2-4 weeks maximum continuous use | 8 |
Population Population not independently verified; see the reference and linked research. Context Reported in Pep-Pedia’s educational protocol table. Study attribution and applicability to this exact product are not independently established. Source interaction and mandatory-choline claims are not established clinical rules. Source tabs Nasal | |||||
No protocols match these filters.
Study and label doses retain their study context. Reference reports are unvalidated practices, not personal treatment instructions. Ranges remain ranges; escalation stages are labeled.
Reported use periods and breaks. These do not establish a safe cycle or prove that breaks prevent tolerance.
Oral
- Use period
- 4-8 weeks continuous use recommended
- Break
- 2-4 weeks break between cycles to prevent tolerance
Reported timing
Morning and early afternoon dosing optimal; avoid late evening due to potential alertness effects
Nasal
- Use period
- 2-4 weeks maximum continuous use
- Break
- 2 weeks break between cycles
Reported timing
Morning administration for cognitive enhancement; allow 15-30 minutes before demanding tasks
Side effects & safety
Evidence limitation
Tested supplements included unexpected drug combinations.
1Evidence limitation
Product surveillance does not quantify intrinsic omberacetam toxicity or establish a safe dose.
1Reported adverse effects
Headache, agitation/anxiety, insomnia/vivid dreams, GI upset or palpitations/BP increase.
Local reactions
Nasal bleeding, congestion/infection or allergy; recent nasal surgery/pathology matters.
Unstudied contexts
Pregnancy/lactation and liver disease need review.
Not a complete safety screen. Discuss health decisions with a qualified clinician.
Combinations & interactions
7 entriesCheck cautions and reported pairings. A compatibility claim does not establish that a combination is safe.
NA Semax amidate
Caution reportedPossible overstimulation.8
Reference report · Pep-Pedia label: SynergisticDihexa
Caution reportedUncharacterized growth-factor effects.8
Reference report · Pep-Pedia label: Use CautionSemax
Unverified pairingUntested cognition pairing.8
Reference report · Pep-Pedia label: SynergisticSelank
Unverified pairingUntested anxiety/cognition pairing.8
Reference report · Pep-Pedia label: SynergisticCerebrolysin
Unverified pairingUntested neurotrophic pairing.8
Reference report · Pep-Pedia label: CompatibleCholine sources
Unverified pairingHeadache-prevention claim unproven; not universally required.8
Reference report · Pep-Pedia label: SynergisticOther nootropic or prescription drugs
Not establishedThe market study detected combinations untested in humans; absence of interaction data is not compatibility evidence.1
Research contextNo matching interactions. Try another name or filter.
Reconstitution
No product-specific preparation or stability instruction was verified. A dilution calculation does not establish suitability for injection.3
Reference preparation details
Reported handling information, not a validated formulation or instruction to prepare an injectable product.
Oral
The source describes 10 mg tablets, capsules or measured powder.
- Form
- Source describes a prepared product
- Reported parameters
- Reported storage: cool and dry, away from light and moisture.
Nasal
Pep-Pedia reports a nasal solution with known pump delivery volume.
- Solvents mentioned
- Sterile saline / Sterile water
- Reported parameters
- Example concentration: 10 mg/mL; amount per spray depends on pump volume. · Reported refrigerated interval: 2–4 weeks.
Appearance & documentation
Appearance and a purity certificate cannot establish sterility, identity, or suitability for injection.
Reported appearanceWhite crystalline powderReported appearanceThird-party testingReported appearanceProper packagingReported appearanceAccurate dosingReported variationHeadache potentialReported concernDiscoloration or clumping
8Available forms
No verified packaging examples included.
Packaging examples, not a market survey. Approved and research products are not interchangeable.
Storage after mixing
Reconstituted research vials
Refrigerated lifetime not established
The checked sources do not establish how long this research preparation remains stable and sterile after mixing.8
Storage notes
8Room temperature, protect from moisture and light
Refrigerate reconstituted solution, protect from light
Storage depends on the formulation, diluent, container, and handling. Follow the specific product label or pharmacist’s instructions.
Evidence limits
View findings →Contemporary confirmatory clinical benefit was not verified in this targeted check.1
2 distinct primary sources or abstracts checked. Evidence may concern a parent compound, individual blend ingredient, animal, or cell model; it does not necessarily establish a benefit for this exact product.
Evidence definitions →Research findings
Limited human dataSource context
Source interaction and mandatory-choline claims are not established clinical rules.
Compound identity & other names
Omberacetam, or Noopept, is a dipeptide-derived small molecule studied for cognitive impairment. Limited clinical reports and animal research do not establish reliable enhancement in healthy users.
No FDA-approved product identified for this exact research entry in the targeted review.
Dipeptide-derived nootropic3
How it may work
Proposed cycloprolylglycine metabolite, glutamate/cholinergic and BDNF/NGF signaling; nasal advantages need direct validation.8
Product quality is a documented concern
Ten tested cognitive-enhancement products included unapproved drugs and unpredictable combinations. Such products cannot be assumed to deliver the identity or amount stated on their labels.
1Older patient study exists
The 2009 paper compared Noopept and piracetam in cognitive disorders after vascular or traumatic brain disease. Its quantitative results remain unreviewed here because the accessible record lacks an abstract.
2Research areas and evidence gaps
Cognition interest. Ten tested cognitive-enhancement products included unapproved drugs and unpredictable combinations. Such products cannot be assumed to deliver the identity or amount stated on their labels.1
- Contemporary confirmatory clinical benefit was not verified in this targeted check.
- A product-specific research-vial quantity was not independently verified in this review.
Additional uses listed by Pep-Pedia
Cognition. Memory, learning and attention goals.8
Neuroprotection. Oxidative, inflammatory and excitotoxic injury models.8
Plasticity. Neurotrophic-factor and synaptic mechanisms; not proof of better real-world performance.8
Nasal delivery. Experimental acute-focus and exposure claims.8
Community reports Unvalidated
Pep-Pedia discusses cognitive impairment research.3
Editorial summary, not a measured community survey, clinical protocol or recommendation.
Search coverage and review status
Checked the older patient-study record and product-surveillance evidence. No newer confirmatory human trial was verified; the 2009 record lacks an accessible abstract.
- Checked
- 2026-10-12
- Search
- "omberacetam" 2025 2026; Noopept piracetam comparative study 2009
- Catalog
- Pep-Pedia ↗ · 4 listed references retained
- Targeted search and selected primary-source checks, not an exhaustive systematic review.
- Preserved bibliography entries marked unreviewed have not had their findings independently verified.
AI-prepared summaries. Independent medical editorial review is pending.
Community poll 10 topics · Pep-Pedia snapshot
Voluntary, unverified reports. These percentages do not measure effectiveness or safety.
Experience
Number of responses to this question: not disclosed.
Duration of use
Number of responses to this question: not disclosed.
Age range
Number of responses to this question: not disclosed.
Gender
Number of responses to this question: not disclosed.
Primary goal
Number of responses to this question: not disclosed.
Effectiveness
Number of responses to this question: not disclosed.
Side effects
Number of responses to this question: not disclosed.
Dosage frequency
Number of responses to this question: not disclosed.
Would recommend
Number of responses to this question: not disclosed.
How discovered
Number of responses to this question: not disclosed.
Source & limitations
The source displays “37 responses” for this profile. This is not a confirmed participant count or a denominator for individual questions.
- Voluntary self-reports from Pep-Pedia visitors; identity, treatment, outcomes and timing are unverified. These data are not efficacy or safety estimates.
- The source displays a profile-wide response label, not a confirmed unique participant count. It stays unchanged across questions. Question-specific denominators and absolute option counts are not exposed.
- Only the top five categories are displayed for some questions. Extra categories are retained as an undisplayed-category count; their labels and percentages are unavailable.
- Displayed percentages are rounded. They may not total 100%, especially where categories are hidden.
- This is a dated snapshot, not a live survey or current recommendation.
References
Original sources and review status. Open a reference to read its summary.
1Five Unapproved Drugs Found in Cognitive Enhancement SupplementsAbstract checked
AI-PREPARED SUMMARY
Testing of ten products found omberacetam and other unapproved drugs, including unexpected combinations and inaccurate quantities. This was product surveillance, not an efficacy trial.
Product quality is a documented concern
Ten tested cognitive-enhancement products included unapproved drugs and unpredictable combinations. Such products cannot be assumed to deliver the identity or amount stated on their labels.
Additional research · Checked 2026-10-12
2Comparative studies of Noopept and piracetam in the treatment of patients with mild cognitive disorders in organic brain diseases of vascular and traumatic originPrimary source checked
AI-PREPARED SUMMARY
The indexed record confirms a patient comparative study. It has no abstract, so quantitative efficacy and dosing results are not asserted here.
Older patient study exists
The 2009 paper compared Noopept and piracetam in cognitive disorders after vascular or traumatic brain disease. Its quantitative results remain unreviewed here because the accessible record lacks an abstract.
Additional research · Checked 2026-10-12
3Pep-Pedia: Omberacetam (Noopept)Community source checked
AI-PREPARED SUMMARY
Secondary editorial profile and reported practices; not clinical validation.
4Neuroprotection in Alzheimer’s Model (2015)No study link suppliedPep-Pedia report · Primary source not checked
AI-PREPARED SUMMARY
Pep-Pedia reports: Human neuronal cultures exposed to amyloid showed less cell death and tau phosphorylation; this is not a patient Alzheimer trial.
Reported population / model
Cellular
Reported study details
Human cortical neurons · β-amyloid/tau phosphorylation model · Multiple concentrations
Pep-Pedia supplies no original study link for this card. Study identity, design, doses and result remain unverified.
Read the Pep-Pedia report ↗Pep-Pedia reference card; original summary of its reported findings · Checked 2026-10-12
5Neurotrophic Factor Expression (2009)No study link suppliedPep-Pedia report · Primary source not checked
AI-PREPARED SUMMARY
Pep-Pedia reports: Rat hippocampal BDNF and NGF messenger RNA reportedly rose about 1.4-fold and 1.3-fold three hours after dosing.
Reported population / model
Animal
Reported study details
Rat · 0.5mg/kg IP · Single dose · Hippocampal analysis
Pep-Pedia supplies no original study link for this card. Study identity, design, doses and result remain unverified. No study link supplied
Read the Pep-Pedia report ↗Pep-Pedia reference card; original summary of its reported findings · Checked 2026-10-12
6Human Cognitive Enhancement Trial (2008)No study link suppliedPep-Pedia report · Primary source not checked
AI-PREPARED SUMMARY
Pep-Pedia reports: A 53-patient active-comparator study reportedly increased MMSE from 26 to 29; absence of a placebo group limits interpretation.
Reported population / model
Human
Reported study details
53 patients · 20mg daily vs Piracetam 1200mg · 56 days · Cerebrovascular/post-traumatic conditions
Pep-Pedia supplies no original study link for this card. Study identity, design, doses and result remain unverified. No study link supplied
Read the Pep-Pedia report ↗Pep-Pedia reference card; original summary of its reported findings · Checked 2026-10-12
7Spatial Memory Restoration Study (2007)No study link suppliedPep-Pedia report · Primary source not checked
AI-PREPARED SUMMARY
Pep-Pedia reports: A mouse impairment model reportedly showed improved spatial memory and altered antibodies to amyloid oligomers; human disease modification is unestablished.
Reported population / model
Animal
Reported study details
Mouse Alzheimer's model · 0.01mg/kg daily · 21 days
Pep-Pedia supplies no original study link for this card. Study identity, design, doses and result remain unverified. No study link supplied
Read the Pep-Pedia report ↗Pep-Pedia reference card; original summary of its reported findings · Checked 2026-10-12
8Pep-Pedia: Omberacetam (Noopept) — route-specific referenceReference page checked; underlying claims require separate verification.Community source checked
AI-PREPARED SUMMARY
Source page checked across available routes. Protocols, cycles, storage, mechanisms and pairing claims are secondary reports; checking the page does not independently validate those claims. Original concise summaries are used here.
Content coverage audit · Checked 2026-10-12